Cosentyx is a medication used to treat various inflammatory conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, which works by blocking a protein called interleukin-17A. According to the FDA, Cosentyx is classified as a pregnancy category B drug, which means that animal studies have not shown any evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Therefore, Cosentyx should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus [3].

A study published in the British Journal of Dermatology in 2018 investigated the safety of Cosentyx during pregnancy. The study included 64 women who were exposed to Cosentyx during pregnancy, either because they were taking the medication before becoming pregnant or because they started taking it during pregnancy. The study found that there were no major birth defects or other adverse outcomes in the babies born to these women. However, the study was limited by its small sample size and lack of a control group [2].

In conclusion, while there is limited data on the effects of Cosentyx on fetal development, animal studies suggest that it is unlikely to cause harm. However, as with any medication, Cosentyx should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Women who are pregnant or planning to become pregnant should discuss the risks and benefits of Cosentyx with their healthcare provider [3].

Sources:
[2] https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.16901
[3] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000ODMemo.pdf